Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperkalemia frequency study of sacubitril/valsartan in patients with severe renal impairment
jRCT1040230154Active, not recruiting
- Sponsor
- Yaizu City Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sacubitril + valsartan in heart failure (HF) (5 arms), sponsored by Yaizu City Hospital. Primary endpoint: Composite hyperkalemia-related endpoint by renal function group. Started Feb 2024; status: active, not recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCT1040230154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040230154.